Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 7;10(4):571.
doi: 10.3390/vaccines10040571.

The Fluctuation Trend of Serum Anti-SARS-CoV-2 IgM/IgG Antibodies Seroprevalence in the Non-COVID-19 Infected Population and Correlation with Peripheral Blood Leukocyte Parameters in Beijing, China, 2021: A Real-World Study

Pan Wang  1   2 , Nan Yang  3 , Yuting Xue  1   2 , Jiansuo Zhou  1   2 , Yonghua Wu  1   2 , Tiancheng Wang  1   2 , Liyuan Cui  1   2
Affiliations

The Fluctuation Trend of Serum Anti-SARS-CoV-2 IgM/IgG Antibodies Seroprevalence in the Non-COVID-19 Infected Population and Correlation with Peripheral Blood Leukocyte Parameters in Beijing, China, 2021: A Real-World Study

Pan Wang et al. Vaccines (Basel). .

Abstract

Since 2019, the coronavirus disease 2019 (COVID-19) global pandemic has caused more than 300 million cases of disease and 5 million deaths. Vaccination has been widely accepted as the most effective measure for the prevention and control of this disease. However, there is little understanding about serum anti-SARS-CoV-2 IgM/IgG levels after inactivated vaccination as well as the relationship with peripheral blood leukocytes in the non-COVID-19 infected population. A total of 16,335 male and 22,302 female participants were recruited in this study, which was conducted in the Peking University Third Hospital located in Beijing (China). The level and seroprevalence of serum anti-SARS-CoV-2 receptor-binding domain (RBD) IgM/IgG and the association with peripheral blood leukocytes classification were investigated. With an increase in the number and percentage of full immunization of COVID-19 vaccinations in Beijing, serum anti-SARS-CoV-2 IgG antibodies levels and seroprevalence were significantly elevated (p < 0.01). The serum anti-SARS-CoV-2 IgG antibodies of 60 years and older persons were significantly lower than that of individuals that are 18~60 years old (p < 0.01), and there was a positive relationship between serum anti-SARS-CoV-2 IgG antibodies levels and peripheral blood lymphocyte count. The investigation of serum anti-SARS-CoV-2 IgM/IgG antibodies and the peripheral hematological index may prompt and help understand the adaptive immune response of vaccination.

Keywords: COVID-19; IgM and IgG antibody; SARS-CoV-2; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
The average of S/CO ratio (A,D), S/CO ratio density (B,E), and distribution (C,F) of serum anti-SARSCoV-2 IgM/IgG antibodies of the present study population in February, March, August, September, October, and November in Beijing.
Figure 2
Figure 2
The positive percentage of serum anti-SARS-CoV-2 IgM/IgG antibodies of the present study population in February, March, August, September, October, and November in Beijing (A,B).
Figure 3
Figure 3
The age distribution and composition of the present study population (A,B).
Figure 4
Figure 4
The average S/CO ratio of serum anti-SARS-CoV-2 IgM/IgG antibodies in the age groups of <18, 18~60, and >60 years old (A,B).
Figure 5
Figure 5
The relationship between the S/CO ratio of serum anti-SARS-CoV-2 IgM/ and IgG in the present study population (A). The association between the age and the S/CO ratio of serum anti-SARS-CoV-2 IgM/IgG in the present study population (B,C). Spearman’s correlation between the S/CO ratio of serum anti-SARS-CoV-2 IgM/IgG and peripheral blood white blood cell classification (D).
See this image and copyright information in PMC

References

    1. Harvey R.A., Rassen J.A., Kabelac C.A., Turenne W., Leonard S., Klesh R., Meyer W.A., Kaufman H.W., Anderson S., Cohen V.I., et al. Real-World Data Suggest Antibody Positivity to SARS-CoV-2 Is Associated with a Decreased Risk of Future Infection. medRxiv. 2020 doi: 10.1101/2020.12.18.20248336. - DOI
    1. Zheng W., Yan X., Zhao Z., Yang J., Yu H. COVID-19 vaccination program in the mainland of China: A subnational descriptive analysis on target population size and current progress. Infect. Dis. Poverty. 2021;10:1–10. doi: 10.1186/s40249-021-00909-1. - DOI - PMC - PubMed
    1. Plebani M., Cosma C., Padoan A. SARS-CoV-2 Antibody Assay after Vaccination: One Size Does Not Fit All. Clin. Chem. Lab. Med. 2021;59:e380–e381. doi: 10.1515/cclm-2021-0703. - DOI - PubMed
    1. He Z., Ren L., Yang J., Guo L., Feng L., Ma C., Wang X., Leng Z., Tong X., Zhou W., et al. Seroprevalence and Humoral Immune Durability of Anti-SARS-CoV-2 Antibodies in Wuhan, China: A Longitudinal, Population-Level, Cross-Sectional Study. Lancet. 2021;397:1075–1084. doi: 10.1016/S0140-6736(21)00238-5. - DOI - PMC - PubMed
    1. Yang M., Cao S., Liu Y., Zhang Z., Zheng R., Li Y., Zhou J., Zong C., Cao D., Qin X. Performance Verification of Five Commercial Rt-Qpcr Diagnostic Kits for SARS-CoV-2. Clin. Chim. Acta. 2022;525:46–53. doi: 10.1016/j.cca.2021.12.004. - DOI - PMC - PubMed

LinkOut - more resources